Loading...

Live Tweeting

Learn more and share your knowledge with the liver community
Join the Live Tweeting @EASLedu for each EASL meeting

EASL EducationFollow

EASL Education
phil_newsome7Phil Newsome@phil_newsome7·
11 Nov

After an inspiring speech by Prof Yamada our four societies will redouble our efforts for hepatitis C elimination #easl #aasld #aleh #apasl

Reply on Twitter 1193867661333151745Retweet on Twitter 11938676613331517459Like on Twitter 119386766133315174521Twitter 1193867661333151745
mromerogomezManuel Romero-Gómez@mromerogomez·
15h

Dr Stephen Harrison presents phase 2 extension on Resmetiron THb agonist promoting lipid lowering, ALT& GGT decrease, improving proC3, PDFF-MRI T1c and adiponectin @AASLDtweets @EASLedu @LITMUS_IMI

2
Reply on Twitter 1194022558850572288Retweet on Twitter 11940225588505722885Like on Twitter 11940225588505722884Twitter 1194022558850572288
ma5RNMaria Reig@ma5RN·
23h

Congratulation Jordi!! #AASLD #Award Very nice presentation by Prof Gores @BCLC_group @hospitalclinic @idibaps @CIBERehd @MayoClinic @AASLDtweets @EASLnews @liverunitclinic @AEEHLiver

4
Reply on Twitter 1193909370238713856Retweet on Twitter 119390937023871385616Like on Twitter 119390937023871385669Twitter 1193909370238713856
liverprofScott Matherly@liverprof·
22h

Dr. Sangro: exciting early data for use of nivolumab (anti-PD1) + ipilimumab (anti-CTLA4) in advanced HCC, second line. Total response rate >30% with 8% complete response. Safety profile acceptable. Phase 3 trial (first line) is in progress 🙏 #LiverMtg19 #hcc #Immunotherapy

Reply on Twitter 1193921724703789063Retweet on Twitter 11939217247037890637Like on Twitter 119392172470378906311Twitter 1193921724703789063
Share
Back To Top